The T-cell clonality assay identifies whether a population of T-cells is derived from a single (monoclonal) or multiple (polyclonal) cells. It utilizes PCR to amplify specific T-cell receptor (TCR) gene segments, followed by fragment analysis or sequencing to determine their unique rearrangement patterns. This assay helps diagnose T-cell lymphomas and leukemias and can be used to monitor minimal residual disease (MRD) and assess treatment response.

This PCR-based molecular test simultaneously detects mutations in two genes—NPM1 and FLT3-ITD—that are crucial for classifying and predicting prognosis in acute myeloid leukemia (AML) patients. It aids in risk stratification and treatment decisions in AML.

Next-Generation Sequencing (NGS) HLA typing High Resolution is a molecular technique that sequences the entire human leukocyte antigen (HLA) genes at high resolution. It provides detailed information about the specific HLA alleles present in an individual, enabling accurate HLA matching for transplantation, disease association studies, and personalized medicine.

NGS Bone Marrow Failure Syndrome (NGS BMFS) is a genetic test that uses Next-Generation Sequencing (NGS) technology to analyze multiple genes associated with inherited bone marrow failure syndromes. These syndromes cause insufficient production of blood cells, leading to various symptoms and complications. NGS BMFS helps diagnose these syndromes, identify the underlying genetic cause, assess disease severity, and guide personalized treatment and management.

NGS Myeloid DNA is a next-generation sequencing (NGS) based test that analyzes multiple genes associated with myeloid malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). This comprehensive test identifies mutations, insertions, deletions, and other genetic alterations that aid in diagnosis, prognosis, treatment selection, and monitoring disease progression in these cancers.

NGS Myeloid RNA is a next-generation sequencing (NGS) based test that analyzes RNA extracted from blood or bone marrow samples to detect fusion genes and other RNA-based abnormalities associated with myeloid malignancies. This test aids in diagnosing and classifying leukemia subtypes, guiding treatment decisions, and monitoring response to therapy.

NGS Myeloid DNA + RNA is a comprehensive next-generation sequencing (NGS) test that analyzes both DNA and RNA extracted from blood or bone marrow samples to identify genetic alterations associated with myeloid malignancies. This test detects mutations, fusion genes, and other abnormalities in multiple genes relevant to diagnosis, prognosis, treatment selection, and monitoring disease progression in myeloid cancers like leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

NGS Clinical Exome Sequencing (CES) is a genetic test that analyzes the protein-coding regions of an individual’s DNA (exome) to identify potential disease-causing mutations. It aids in diagnosing rare genetic disorders, understanding complex conditions, and guiding personalized treatment plans. CES is particularly useful when traditional genetic tests are inconclusive or when multiple genes could be involved in a patient’s condition.

NGS Whole Exome Sequencing (WES) is a genetic test that uses Next-Generation Sequencing (NGS) technology to analyze the protein-coding regions of an individual’s DNA (exome). This comprehensive test identifies potential disease-causing mutations in thousands of genes simultaneously, aiding in diagnosing rare genetic disorders, understanding complex conditions, and guiding personalized treatment plans. WES is particularly useful when traditional genetic tests are inconclusive or when multiple genes could be involved in a patient’s condition.

Complete Blood Count (CBC) is a blood test that measures the number and characteristics of your red blood cells, white blood cells, and platelets. It helps evaluate overall health, diagnose and monitor various conditions like anemia, infection, and blood disorders.